Open Access

Mutation allele‑specific multiplex PCR for the detection of BRAFV600E mutations in breast carcinomas

  • Authors:
    • Rafiqa Eachkoti
    • Sanah Farooq
    • Ruby Reshi
    • Muneeb U. Rehman
    • Tabassum Rashid
    • Nisar Ahmed Naikoo
    • Shajurul Amin
    • Akbar Masood
  • View Affiliations

  • Published online on: June 6, 2019     https://doi.org/10.3892/wasj.2019.14
  • Pages: 145-150
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The oncogenic activation of BRAF is commonly reported in human cancers; however, it is an understudied research area in breast cancer. In this study, we took the initiative to screen breast cancer patients for the most prevalent hotspot BRAFV600E mutation and discuss its clinical implications. Mutational screening was performed using a highly sensitive technique, mutation allele‑specific multiplex PCR (MASMP), the results of which were previously confirmed by sequencing the product and sensitivity compared to direct DNA sequencing. In total, BRAFV600E mutation status was analysed in 50 breast tumour samples and an equal number of adjacent normal tissues. Mutational screening by MASMP revealed its presence in 12% of the breast cancer patients. Association analysis revealed that BRAFV600E mutation was significantly present in oestrogen receptor (ER)/progesterone receptor (PR)‑negative (χ2=4.36, P=0.03) and mostly in triple‑negative breast cancers (TNBCs) (χ2=2.5, P=0.11). In addition, although not significant, BRAFV600E‑positive breast cancers were mostly found in older‑aged (χ2=1.10, P=0.29) and in post‑menopausal women (χ2=1.10, P=0.29). No significant association was found between BRAFV600E‑mutated breast cancers and traditional poor prognostic factors, such as clinical tumour stages III and IV (χ2 0.036, P=0.84) and a poorly differentiated (PD) histopathological grade (χ2 0.04, P=0.82).On the whole, positivity for BRAFV600E was noted in a fraction of elderly post‑menopausal women, predominantly of the ER/PR‑negative and/TNBC molecular subtype. MASMP was found to be a simple, sensitive and effective method for the rapid detection of BRAFV600E‑mutated breast cancers. For these types of breast cancers, BRAF‑targeted therapies in place of endocrine therapy, at least in BRAFV600E‑positive ER/PR‑negative/TNBC, may be considered as possible targeted therapy in the future.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar

2 

Wani MA, Jan FA, Khan NA, Pandita KK, Khurshid R and Khan SH: Cancer trends in Kashmir; common types, site incidence and demographic profiles: National Cancer Registry 2000-2012. Indian J Cancer. 51:133–137. 2014.PubMed/NCBI View Article : Google Scholar

3 

Qureshi MA, Khan SM, Masoodi MA, Qureshi U, Ain Q, Jan Y, Haq I and Sheikh ZA: Epidemiology of cancers in Kashmir, India: An analysis of hospital data. Adv Prev Med. 2016(1896761)2016. View Article : Google Scholar

4 

Malvia S, Bagadi SA, Dubey US and Saxena S: Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 13:289–295. 2017.PubMed/NCBI View Article : Google Scholar

5 

Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.

6 

Garnett MJ and Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004.PubMed/NCBI View Article : Google Scholar

7 

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002.PubMed/NCBI View Article : Google Scholar

8 

Hall RD and Kudchadkar RR: BRAF mutations: Signalling, epidemiology, and clinical experience in multiple malignancies. Cancer Control. 21:221–230. 2014.PubMed/NCBI View Article : Google Scholar

9 

Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW and Schutte M: Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res. 5:195–201. 2007.PubMed/NCBI View Article : Google Scholar

10 

Tilch E, Seidens T, Cocciardi S, Reid LE, Byrne D, Simpson PT, Vargas AC, Cummings MC, Fox SB, Lakhani SR and Chenevix Trench G: Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Res Treat. 143:385–392. 2014.PubMed/NCBI View Article : Google Scholar

11 

Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, et al: Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 134:333–343. 2012.PubMed/NCBI View Article : Google Scholar

12 

Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G and Vitale M: Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 154:341–348. 2006.PubMed/NCBI View Article : Google Scholar

13 

Eachkoti R, Farooq S, Syeed SI, Wani HA, Majid S and Pampori MR: Prevalence and prognostic relevance of BrafV600E mutation in colorectal carcinomas from Kashmir (North India) valley. Mutagenesis. 33:225–230. 2018.PubMed/NCBI View Article : Google Scholar

14 

Bui MM, Riben MW, Allison KH, Chlipala E, Colasacco C, Kahn AG, Lacchetti C, Madabhushi A, Pantanowitz L, Salama ME, et al: Quantitative image analysis of human epidermal growth factor receptor 2 immunohistochemistry for breast cancer: Guideline from the college of american pathologists. Arch Pathol Lab Med. Jan 15. 2019.(Epub ahead of print). PubMed/NCBI View Article : Google Scholar

15 

Fan H and Gulley ML: DNA extraction from fresh or frozen tissues. Methods Mol Med. 49:5–10. 2001.PubMed/NCBI View Article : Google Scholar

16 

El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F and Kurzrock R: BRAF mutations in advanced cancers: Clinical characteristics and outcomes. PLoS One. 6(e25806)2011.PubMed/NCBI View Article : Google Scholar

17 

Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MF, Pucciarini A, Bigerna B, Pacini R, Wells VA, et al: BRAF mutations in hairy-cell leukemia. N Engl J Med. 364:2305–2315. 2011.PubMed/NCBI View Article : Google Scholar

18 

Jung YY, Jung WH and Koo JS: BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody. Int J Clin Exp Pathol. 9:1545–1556. 2016.

19 

Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J and Kurzrock R: Genomically driven tumors and actionability across histologies: BRAF-Mutant cancers as a paradigm. Mol Cancer Ther. 15:533–547. 2016.PubMed/NCBI View Article : Google Scholar

20 

Bösmüller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A and Fend F: Detection of the BRAF V600E mutation in serous ovarian tumors: A comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 44:329–335. 2013.PubMed/NCBI View Article : Google Scholar

21 

COSMIC: Catalogue of Somatic Mutations in Cancer. Wellcome Trust Sanger Institute; urihttp://cancer.sanger.ac.uk/cancer-genome/projects/cosmicsimplehttp://cancer.sanger.ac.uk/cancer-genome/projects/cosmic. Accessed January 2, 2014.

22 

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6(pl1)2013.PubMed/NCBI View Article : Google Scholar

23 

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011.PubMed/NCBI View Article : Google Scholar

24 

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomized controlled trial. Lancet. 380:358–365. 2012.PubMed/NCBI View Article : Google Scholar

25 

Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation. GlaxoSmithKline, London, 2013. urihttp://us.gsk.com/en-us/media/press-releases/2014/tafinlar-receives-FDA-breakthrough-therapy-designation-for-non-small-cell-lung-cancer-with-braf-mutation/simplehttp://us.gsk.com/en-us/media/press-releases/2014/tafinlar-receives-FDA-breakthrough-therapy-designation-for-non-small-cell-lung-cancer-with-braf-mutation/. Accessed January 13, 2014.

26 

Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI: Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 23:1277–1283. 2013.PubMed/NCBI View Article : Google Scholar

27 

Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC and Kurzrock R: BRAF mutant gastrointestinal stromal tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 4:310–315. 2013.PubMed/NCBI View Article : Google Scholar

28 

Robinson GW, Orr BA and Gajjar A: Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 14(258)2014.PubMed/NCBI View Article : Google Scholar

29 

Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D and Geoerger B: Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 61:1101–1103. 2014.PubMed/NCBI View Article : Google Scholar

30 

Samuel J, Macip S and Dyer MJ: Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 370:286–288. 2014.PubMed/NCBI View Article : Google Scholar

31 

Munoz J, Janku F, Cohen PR and Kurzrock R: Erdheim-Chester disease: Characteristics and management. Mayo Clin Proc. 89:985–996. 2014.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

May 2019
Volume 1 Issue 3

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Eachkoti, R., Farooq, S., Reshi, R., Rehman, M.U., Rashid, T., Naikoo, N.A. ... Masood, A. (2019). Mutation allele‑specific multiplex PCR for the detection of BRAFV600E mutations in breast carcinomas. World Academy of Sciences Journal, 1, 145-150. https://doi.org/10.3892/wasj.2019.14
MLA
Eachkoti, R., Farooq, S., Reshi, R., Rehman, M. U., Rashid, T., Naikoo, N. A., Amin, S., Masood, A."Mutation allele‑specific multiplex PCR for the detection of BRAFV600E mutations in breast carcinomas". World Academy of Sciences Journal 1.3 (2019): 145-150.
Chicago
Eachkoti, R., Farooq, S., Reshi, R., Rehman, M. U., Rashid, T., Naikoo, N. A., Amin, S., Masood, A."Mutation allele‑specific multiplex PCR for the detection of BRAFV600E mutations in breast carcinomas". World Academy of Sciences Journal 1, no. 3 (2019): 145-150. https://doi.org/10.3892/wasj.2019.14